New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing

May 24, 2021Filed Under: Press ReleasesBy admin

“How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” authored by Alex Brill and Christy Robinson, explains how reference biologic manufacturers create thickets of overlapping, weaker follow-on patents to keep competitors from entering the market. The paper highlights how originators have strong incentives to protect their profit streams and have found patent thickets to be an easy way to significantly extend the duration of monopolies in the US, preventing access to more affordable medicines for patients.

New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year

September 14, 2020Filed Under: Press ReleasesBy admin

Report details five instances of product hopping that collectively cost $4.7 billion annually.

New Analysis Situates COVID-19 Alongside 1918 Pandemic, Predicts 12 Million–26 Million Hospitalizations

April 16, 2020Filed Under: Press ReleasesBy admin

A new report released today by Matrix Global Advisors (MGA) finds that COVID-19 is likely as severe as the 1918 pandemic, the worst pandemic in the twentieth century. MGA evaluated COVID-19 data using the Centers for Disease Control and Prevention’s Pandemic Severity Assessment Framework (PSAF) and found that the current pandemic’s clinical severity (how sick the virus makes people) and transmissibility (how contagious the virus is) are the highest measurable by that tool.